Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2010. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the SmithKline Beecham Mid-Term Incentive Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions related to dividend reinvestment.
Material Changes
On April 13, 2010, administrators notified the company of an increase in interests in Ordinary share ADRs for specific individuals following the reinvestment of dividends paid on April 8, 2010. The transaction price was $38.86 per ADR. The specific increases were:
- Mr. E J Gray: 18.92 ADRs
- Mr. D J Phelan: 573.65 ADRs
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total number of ADRs held by Mr. E J Gray and Mr. D J Phelan post-transaction.
- Confirm the dividend amount reinvested to calculate the total value of the transaction.
- Check subsequent filings for any further changes in director holdings.